Open access peer-reviewed chapter

Heart Failure in Sub-Saharan Africa

Written By

Okechukwu S. Ogah, Adewole Adebiyi and Karen Sliwa

Submitted: May 1st, 2018 Reviewed: November 6th, 2018 Published: May 20th, 2019

DOI: 10.5772/intechopen.82416

Chapter metrics overview

1,584 Chapter Downloads

View Full Metrics


Sub-Saharan Africa (SSA) is currently experiencing multiple burden of disease as a result of demographic and epidemiologic transition. This is occasioned rapid urbanization, unhealthy diets rich in fats and salt, western lifestyle and sedentary living. Heart failure (HF) has become a global public health issue. It is associated with high morbidity and mortality, frequent hospitalization and high economic cost. In SSA, HF is a disease of young and middle-aged adults with the attendant high disability-adjusted life years. This is unlike to the clinical profile and pattern of HF in high-income countries of North America, Western Europe and Japan where HF is a disease of the elderly. In addition, while ischaemic heart disease is the commonest aetiologic risk factor for HF in high income countries, HF in SSA is essentially non-ischaemic in origin. Hypertensive heart failure, dilated cardiomyopathy, rheumatic heart disease, pericardial diseases and HIV associated cardiomyopathy are the common risk factors. The chapter reviews the contemporary information on HF in SSA in terms of socio-demographic features, clinical characteristics, aetiological risk factors, management, prognosis and economic burden.


  • heart failure
  • cardiac failure
  • cardiac dysfunction
  • sub-Saharan Africa
  • Africa

1. Introduction

Africa has multiple burden of disease. While the continent is still grabbling with traditional communicable and infectious diseases, there is increasing burden of non-communicable diseases (NCDs) such as hypertension, diabetes mellitus, cancers, etc., in addition to HIV/AIDS, malnutrition, wars and conflicts. The rapid epidemiologic transition from communicable to non-communicable diseases can be attributed to rapid urbanization, unhealthy diets rich in fats and salt, western lifestyle and sedentary living.

The global burden of disease 2015 report ranked NCDs only second to HIV/AIDS as the commonest cause of morbidity and mortality in SSA. It is projected that in the near future, NCDs will become the bigger cause of mortality in the region.

Like in other parts of the world, heart failure (HF) is associated with high morbidity and mortality, frequent hospitalization and high economic cost. In sub-Saharan Africa, HF has been shown to affect young and middle-aged adults with the attendant high disability-adjusted life years. This is contrary to the pattern of HF in high-income countries of North America, Western Europe and Japan where HF is essentially a disease of the elderly. Furthermore, while ischaemic heart disease is the commonest aetiologic risk factor for HF in high-income countries, HF in SSA is essentially non-ischaemic in origin. Hypertensive heart failure, dilated cardiomyopathy, rheumatic heart disease, pericardial diseases and HIV-associated cardiomyopathy are the common risk factors.

The aim of this chapter is to review contemporary information on HF in SSA in terms of socio-demographic features, clinical characteristics, aetiological risk factors, management, prognosis and economic burden. We shall conclude with gaps in knowledge and possible feature directions.


2. Sub-Saharan Africa

SSA is the geographical term used to describe the region of the African continent that lies south of the Sahara Desert. It covers a land area of 24.3 million square meters. In 2007, the population of the region was estimated to 800 million with a growth rate of 2.3% per annum. The United Nation has projected a population of 1.5 billion by 2050 [1]. Figure 1 shows the countries that comprise the region including the sub-regions of: (1) West Africa, (2) Central Africa or Middle Africa, (3) Eastern Africa, (4) Horn of Africa and (5) Southern Africa. [2] The population of SSA is very diverse both physically and culturally and they have differing ethnic background. For instance, the Negroes inhabit most of West Africa; the Tuaregs Nilo-Hamites occupy the east horn of the continent, while the Bantus inhabit the Central and Southern Africa. There are also the Hottentots in rural Namibia and the pygmies of the Congo Basin [2].

Figure 1.

Map of sub-Saharan Africa.


3. Historical perspective

Albert Ruskin Cooke [3] appears to be one of the earliest workers to have reported on the pattern of diseases in Africa. In 1901, he analysed 1500 in-patients, whom he met at a hospital in Uganda. He observed that 3% of all hospital admissions and 6% of all medical admissions were due to heart disease. He wrote ‘Valvular diseases of the heart are common’, ‘Atheroma and aneurysms are very rare, although syphilitic endarteritis obliterans is probably common’ and ‘high tension pulses are not often met with’ [4].

Fifty years later, Sharper and his colleagues analysed 1957 medical admission seen at the Mulago Hospital in Kampala and noted that cardiovascular disease was responsible for 8–10% of medical admissions. The main cardiac conditions reported were hypertensive heart disease, rheumatic heart disease, endomyocardial fibrosis and syphilitic heart disease [5, 6].

Similar work carried out in other countries in the 1960s and 1970s reported similar percentage that cardiovascular diseases are of all medical admissions. For example, 11.2% for Ibadan, Nigeria [7], 8.6% for Mombasa, Kenya [8], 8.8% for Dar es Salaam, Tanzania [9], 4.3% for Blantyre, Malawi [10] and 8.6% for Sekhukhuneland, South Africa [11].

Studies in the late 1970s, 1980s and in the 1990s also show the prominence of hypertensive heart disease, rheumatic heart disease and dilated cardiomyopathy as the main causes of heart disease in the region and decreasing incidence of syphilitic heart disease.

More recent studies have used echocardiography in the evaluation of heart diseases in the region. These have documented peculiar characteristics of heart diseases in sub-Saharan Africa [12, 13, 14, 15, 16, 17, 18, 19, 20].


4. Contemporary epidemiology of HF in SSA

4.1. Incidence and prevalence

There is lack of population-based incidence and prevalence studies in SSA. The reported hospital prevalence studies indicate that HF is responsible for 9.4–42.5% of all medical admissions and 25.6–30.0% of admissions into the cardiac units.

4.2. Socio-demographic characteristics

4.2.1. Age at presentation

HF in SSA is a disease of young and middle age. It is commoner between the third and fifth decade of life when the individuals are in the prime of their life. The mean age ranges from 36.5 to 61.5 years (Figure 2A) [15, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. In high-income countries, it is commoner in the seventh decade of life.

Figure 2.

(A) Mean age of HF patients from various studies in SSA. (B) Proportion of men in various HF studies in SSA.

4.2.2. Gender distribution

There is varying gender distribution. It is commoner in men in countries where hypertensive heart disease is the commonest aetiology. Women are predominating where rheumatic heart disease and cardiomyopathies (peripartum cardiomyopathy) is common (Figure 2B) [15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39].

4.3. Clinical profile

4.3.1. Mode of presentation and diagnosis

Most patients present in advanced heart failure (NYHA class III and IV) [26, 40]. Diagnosis of HF in SSA is mostly based on clinical features, mostly by the Framingham criteria (in 28.6%) and European Society of Cardiology criteria (in 20%). Support facilities and services for diagnosis of HF in SSA are generally lacking in many parts of SSA [41]. Common diagnostic tools employed are chest radiography, 12-lead ECG and echocardiography. Biomarkers are less often used because of non-availability and high cost [39, 42].

4.3.2. Symptoms and signs

Common symptoms of HF in SSA include cough, dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, pedal oedema and easy fatiguability. Rales, displaced apex beat, elevated jugular venous pressure and third heart sound are common signs. Others include peripheral oedema, tender hepatomegaly and systolic murmur [18].

Baseline rales and change to day 7 or discharge in general well-being are associated with death or readmission through 180 days. In addition, baseline orthopnoea, rales, oedema, oxygen saturation and changes to day 7 or discharge in respiratory rate or general well-being have been shown to be predictive of 6-months readmission or death [37].

4.3.3. Clinical class of heart failure

HF patients in SSA most often than not present in severe HF (NYHA class III and IV) [26, 27, 40].

In the INTER-CHF study, 35.5 and 20.9% of African HF patients were in NYHA classes III and IV, respectively.

4.3.4. Precipitating factors

Precipitants of HF in SSA are infections (especially chest and urinary tract infection), uncontrolled hypertension and arrhythmias especially atrial fibrillation. Other precipitants include anaemia, excessive physical activity and electrolyte imbalance (e.g. hyponatremia and hypokalemia) [17, 18, 43].


5. Aetiology HF in SSA

Hypertensive heart disease is the identified number one risk factor for HF in SSA. It is responsible for about 39.2% (95% CI: 32.6–45.9%). This is followed by dilated cardiomyopathy, 22.7% (95% CI: 16.8–29.1%) and rheumatic heart disease, 13.8% (95% CI: 9.9–18.0%). These three aetiological risk factors are responsible for over 75% of HF in the region. Ischaemic heart disease accounts for about 7.2% (95% CI: 4.1–11%). The general trend is that ischaemic heart disease is gradually rising in many parts of SSA. Table 1 shows the aetiology of HF from recent publications from SSA.

Author Year Country Mode Number HHD (%) DCM (%) RHD (%) IHD (%) PPCM (%) PDX CHD(%) CP (%)
Kingery [29] 2017 Tanzania Prospective 145 42.8 19.3 6.2 7.6
Boombhi [21] 2017 Cameroon Retrospective 148 30.16 28.57 6.35 3.18 3.96 8.73
Traore [35] 2017 Ivory Coast Retrospective 257 22.9 55.57 11.23
Ansa [209] 2016 Nigeria Retrospective 144 48.6 35.4 1.4
Abebe [25] 2016 Ethiopia Retrospective 311 16.1 12.5 15.8 4.5
Dokainish [26] 2015 Multi-country Prospective 1294 35 14.5 7.2 20
Makubi [210] 2014 Tanzania Prospective 427 45 28 12 9
Ogah [18] 2014 Nigeria Prospective 452 78.5 7.5 2.4 0.4 3.3 4.4
Pio [28] 2014 Togo Prospective 297 43.1 19.2 11.8 2.7 2.7
Pio [32] 2014 Togo Retrospective 376 42.8 5.8 2.7 15.4 1.1 2.7 2.1
Kwan [211] 2013 Rwanda Retrospective 138 8 54 25 0
Massoure [211] 2013 Djibouti Prospective 45 18 7 13
Ojji [212] 2013 Nigeria Prospective 1515 60.6 12 8.6 0.4 5.3
Damasceno [27] 2012 Multi-country Prospective 1006 45.4 18.8 14.3 7.7 7.7 6.8
Onwuchekwa [213] 2009 Nigeria Retrospective 423 56.3 12.2 4.26 0.24 0.24 2.13
Stewart [17] 2008 South Africa Prospective 884 33 35 9
Ogah [34] 2008 Nigeria Retrospective 1441 56.7 3 3.7 0.6 1.8 1.6
Familoni [214] 2007 Nigeria Prospective 82 43.4 28 9.8 8.5 3.7
Owusu [215] 2007 Ghana Prospective 167 42.5 17.4 21.6 3.6 4.2 2.4 2.4
Kingue [216] 2005 Cameroon Retrospective 167 54.5 26.3 24.6 2.4
Thiam [217] 2003 Senegal Prospective 170 34 18.9

Table 1.

Aetiology of heart failure in some studies conducted in SSA since the year 2000.

HHD = hypertensive heart disease, DCM = dilated cardiomyopathy, RHD = rheumatic heart disease, IHD = ischaemic heart disease, PPCM = peripartum cardiomyopathy, CHD = congenital heart disease, PDX = pericardial disease, CP = cor pulmonale.

5.1. Aetiological risk factor for HF in SSA

5.1.1. Hypertensive heart disease

Many years ago, Donnison [44] reported that hypertension was uncommon in Africa. This observation was later supported by the post-mortem studies by workers like Jex-Blake [45], Vint [46] as well as clinical study by William [47] in 1941. However, by 1946, workers started reporting on the impact of hypertension on the cardiovascular health of the African. Davies [48] noted that hypertensive heart disease was the commonest cause of congestive heart failure in Kampala. Similar report was also noted in South Africa [49]. Within same period, many other authors from different parts of Africa also documented that the disease is common in the continent, occasionally with prevalence similar to data from Europe and America.

It is known that in isolated and primitive areas of the continent, the prevalence of hypertension is very low and in these populations, blood pressure remains within a narrow range throughout adult life [50]. Blood pressure rises modestly with age in rural dwellers and much more in those who live in the cities.

More recent data from the continent suggest that hypertension is a major cause of cardiac morbidity and mortality [51, 52]. High blood pressure is in fact regarded as the foundation of cardiovascular disease in Africa [53]. In a recent systematic review of hypertension survey in Africa, it was shown that hypertension increased from 54.6 million cases in 1990 to 130.2 million in 2010. The prevalence is projected to rise to 216.8 million cases by 2020, each with an age-adjusted prevalence of 19.1% (13.9, 25.5), 24.3% (23.3, 31.6) and 25.3% (24.3, 39.7), respectively [54].

In the Heart of Soweto study, among the 1196 persons with the diagnosis of secondary hypertension, 682 or 57% (mean age 60 ± 14 years) had hypertensive HF [16]. In the INTERHEART study, hypertension was reported as a strong contributor to the hazards of CVD in black Africans, with an odd ratio of 7.0 versus 2.3–3.9 in other ethnic groups (p < 0.0002) [55].

Hypertension in Africa is associated with body weight, lower intake of potassium and salt sensitivity [56]. The peak age group is 40–49 years. Men are affected more than women. The patterns of presentation of hypertensive HF vary. Some present with acute left ventricular failure and severely elevated blood pressure. A sub-group present with HF and normal blood pressure which tends to rise as the HF is being treated. And yet a third group present with HF and normotension all through. The last group is usually difficult to differentiate from dilated cardiomyopathy in the absence of other signs of long-standing hypertension [57].

The mortality attributable to high blood pressure in most West African Countries ranges between 3 and 7% and cardiovascular mortality is in the range of 20–45% [58]. Women may have added morbidity in Africa if the role of hypertension in pregnancy is factored in. Hypertension is largely asymptomatic until end-organ damage ensues and this is partly responsible for late diagnosis of the disease. Inadequate screening and sub-optimal health facility utilization are also implicated. Therefore, early diagnosis and appropriate therapy would lead to a significant reduction in the prevalence of hypertensive HF in Africa [59].

5.1.2. Rheumatic heart disease (RHD)

It is estimated that 12 million people live with the disease and it results in about 400,000 deaths each year. Two million people will require repeated hospital admission and over a million will need surgery to improve their quality of life. It is common in areas with poor housing condition and an indicator of their plight.

Like hypertension, this was initially thought to be uncommon in Africa [44]. But Cooke in 1901 reported that valvular diseases are common in the continent [3]. This was also supported by reports by other workers [60]. Post-mortem studies have been inconsistent. This may be due to the attitude of Africans towards autopsy.

SSA has a high prevalence of RHD which is in the range of 1–14/1000 children [61, 62, 63]. Echocardiography-based population studies report higher prevalence of 7.5–51.6/1000 children [64, 65]. School surveys have given a prevalence of 2.7/103 in Kenya [66], 4.3/103 in Ethiopia [67] and 6.9/103 in South Africa [68] (among black children). Marijon et al. reported a prevalence of 30/103 from an echocardiography-based school survey [69].

RHD accounts for 12–32% of cardiovascular admissions in SSA. Recent reports suggest that that 6.6–34% of CV-related hospital admissions or echocardiographic data in SSA are due to RHD and up to 2.3% of pregnant women have the disease [70, 71, 72, 73, 74].

There are peculiar features of rheumatic heart disease in Africa (similar to reports from other tropical environments). These are the young age at presentation, the severity of the lesions, as well as the high mortality associated with it. History of rheumatic fever can be obtained in only less than 50% of patients. Pure mitral incompetence and mixed mitral valve disease were the commonest valvular lesions that were demonstrated [75]. This is consistent with the findings of other workers in Africa [74, 76, 77, 78]. A rheumatic carditis has been shown to run a more fulminant course in sub-Saharan Africa (like in other tropical countries) compared to the developed countries [79, 80, 81, 82]. In earlier studies, 33% of 124 mitral valvotomies were in patients under the age of 16 years in one report from Kenya.

The disease appears to be commoner in women. Events in women’s life such as pregnancy frequently unmask the condition [83]. Morbidity and mortality is said to be high especially in women and young people [83, 84]. Mortality at 6 month is estimated as 17.8% [85]. In one report from Ethiopia, the annual mortality from RHD is as high as 12.5%, and 70% of such deaths were before the age of 26 years [67].

Sliwa et al. [86] reported on the characteristics of 344 adult rheumatic heart disease cases in the Heart of Soweto study. The disease was commoner in black women (68%). The most common valvular lesion (n = 204, 59%) was mitral regurgitation (MR), with 48 (14%) and 43 (13%) cases, respectively, having combination lesions of aortic plus MR and mixed mitral VHD. Impaired systolic function was demonstrated in 28/204 cases (14%) of predominant MR and in 23/126 cases (18%) with predominant aortic regurgitation. The finding from the study makes a case for the first episode of RHD to be made a notifiable condition in high-burden countries in order to ensure control of the disease through register-based secondary prophylaxis programmes.

In many countries in SSA, facilities for accurate diagnosis are unavailable. Treatment options such as valvotomy, valvuloplasty and prosthetic valve replacement are either unavailable or unaffordable to a vast majority of the population. Worse still secondary preventive measures are also either unavailable or unaffordable.

The lack of infrastructure, political, economic and social instability, malnutrition and poverty are all factors implicated in the high prevalence of rheumatic fever in Africa which is, otherwise, largely preventable [80]. This culminates in a great burden of rheumatic valvular heart disease and infective endocarditis.

5.2. The cardiomyopathies

Dilated cardiomyopathy (DCM), endomyocardial fibrosis (EMF) and peripartum cardiomyopathy (PPCM) are common and endemic in SSA. Other forms of cardiomyopathy are less common.

5.2.1. Dilated cardiomyopathy (DCM)

DCM is a major cause of HF in SSA. It has been plagued with diagnostic and therapeutic challenges due to lack of appropriate facilities, definitive diagnosis and interventions in resource-poor African centres. It typically presents with progressive HF and is associated with high mortality. In one study, the 4-year mortality was found to be 34%.

There are marked regional differences in the pathogenesis of dilated cardiomyopathy in Africa. The causative factors that have been implicated in several studies across Africa include infection [87, 88] and myocarditis [89, 90], ‘burnt out’ untreated hypertension [91], genetic factors, alcohol, nutritional deficiencies, autoimmune mechanisms, iron overload and pregnancy [92].

The current concept is that 30% of the disease has genetic basis. Familial DCM is caused by a mutation in more than 25 chromosome loci. The genes affected are those encoding contractile, cytoskeleton and calcium regulatory proteins.

In 1975, Owor and Rwomushana reported the first case of familial DCM in Africa [93]. They described twin brothers who were affected by the condition in Uganda. Subsequently, other workers have documented familial DCM in other parts of SSA especially from South Africa [94]. However, there are no systematic family studies of the condition in SSA. Some gene association studies have, however, been done especially in South Africa. Some of the findings include:

  1. An association with HLADR1 and DRW10 antigens suggesting possible genetically determined immune factors may be responsible for the disease [95, 96].

  2. An association with mutation in troponin T-gene (Arg141Trp) [97] and mitochondrial T16185c polymorphism.

On the other hand, there is no evidence of association with cardiac (ACTC1) and skeletal (ACTA1) alpha-actin gene, alpha-2c adrenoceptor (ADRB2c) gene, beta-1 adrenoceptor (ADRB1) gene and tumour necrosis factor-alpha (TNFA) gene.

Some data suggest the immune-modulating agent pentoxifylline may be beneficial in the management of DCM in the region. In one trial, patients on this agent had improvement in effort tolerance, left ventricular function and trend towards lower mortality than those on standard treatment for HF [98].

In a 14-year follow-up of DCM patients in South Africa, a mortality of 10% per year was recorded for both familial and idiopathic DCM. Heart transplantation was an independent predictor of survival, while NYHA III and IV and use of digoxin were associated with poor outcome.

5.2.2. Endomyocardial fibrosis (EMF)

This is a form of restrictive cardiomyopathy in which there is a deposition of fibrous tissue in the mural endocardium resulting in impaired diastolic function as well as valvular dysfunction resulting from entrapment of papillary muscles of the atrioventricular valve. It occurs mainly in the tropical and subtropical areas of Africa. It was first described by William in 1938. It is also called Davies disease because of the seminal work done by Davies on this disorder in Uganda [99, 100, 101]. A comprehensive description of the clinical features has been documented by Hutt [102] as well as other workers [103, 104]. Recently, Mocumbi et al. have suggested diagnostic criteria for diagnosis [105].

EMF has been reported in at least 17 SSA countries: Congo, Cameroon, Egypt, Ethiopia, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria, Senegal, South Africa, Sudan, Tanzania, Uganda, Zambia and Zimbabwe. It has also been reported in India and South America. It is rare in Northern and Southern Africa. Right-sided EMF appears to be commoner. The peak age incidence is 11–15 year in both sexes. In a population-based study in Mozambique, a prevalence of 8.9% was found.

EMF is a disease of childhood and early adolescence. It has also been reported in older adults and infants. A second peak of incidence has been shown during the reproductive age of women. The preponderance of one gender over the other is inconsistently reported. In a large database from Mozambique, it was reported to be more prevalent in males.

The pathophysiology postulated is as follows: endocardial thickening of the ventricles leads to cardiac constriction or restriction and atrioventricular valvular incompetence resulting in regurgitation. The right ventricular cavity is usually obliterated from below by the advancing fibrosis of layered mural thrombi. In severe and late cases, the papillary muscles are buried in a layer of fibrous tissue leading to functionless tricuspid valve and aneurysmal right atrium. When the left ventricle is involved, dense fibrous tissues are deposited at the apex, spreading around the cavity of the LV or may first appear around the papillary muscles of the posterior cusp of the mitral valve (leading to anchoring of the muscle and valvular regurgitation) [99, 104].

Chronic pericardial effusion commonly complicates right-sided EMF, while pleural effusion is commoner with left or biventricular disease [104]. The clinical features depend on the stage of the disease, the anatomical damage done on the affected valve as well as the resultant effect on heart function. An initial illness with fever, chills, night sweats, facial swelling and urticaria can occur and is reported in 30–50% of cases. This can be fatal within months but little is known about this phase of the disease [104].

In left-sided EMF, the ventricle is not enlarged and there is almost always mitral incompetence and a loud pulmonary component of the second heart sound and progressive pulmonary hypertension. There is usually an early third heat sound. When the right ventricle is involved, the classical picture is that of a young patient with ‘egg on stick’ or ‘orange on stick’ appearance (massive ascites and minimal pedal oedema; often with delayed puberty, some exophthalmos and central cyanosis) [104]. The arterial pulse is usually of small volume or feeble. Atrial fibrillation is common. Massive pericardial effusion or a rotated heat (because of massive right atrium) could give an impalpable heart. An abrupt third heart sound is common but murmur may be absent.

The pathogenic process is explained by eosinophil and its constituents. The suggested sequel is as follows [104]:

  1. A trigger to eosinophilia (helminthic or other infections and liberation of eosinophilic major basic proteins and cationic proteins which are toxic to the cardiac cells as well as other cells in the body;

  2. The damaged endocardium serves as a nidus for thrombus formation;

  3. Thrombus formation builds up due to release of platelet-activating factors by the eosinophils;

  4. Further mural thrombi are laid down at the original and adjacent sites leading to the formation of fibrotic mass.

Although this explanation appears plausible, it does not offer reason why the disease is rare in some parts of the tropics, the reported ethnic differences [106] and some familial cases of EMF [107].

Despite the fact that the aetiology of this condition has not been resolved by scientist since the first description, the volume of publication on it has dwindled in the last decade. The cause has remained a mystery despite several proposed aetiological factors [108]. Some of the factors that have been implicated in the past include: (1) infections/infestations, for example, cardiotropic viruses, mycoplasma pneumonia, malaria, schistosomiasis, (2) autoimmunity, (3) Hypereosinophilia, (4) genetics and (5) traditional medications.

Trend in the incidence and prevalence of EMF has not been well studied in SSA. Ellis et al. showed that the prevalence has not changed in Uganda [109]. On the other hand, in Nigeria, EMF was shown to have declined from 10% in the 1960/1970s to 0.02% from medical admissions and 0.04% for cardiac-related admissions in the first decade of twenty-first century. This may not be unconnected with improvement in health-care delivery as well as control of communicable diseases in that part of the country [110].

The prognosis of EMF is poor. The survival of patients after diagnosis is about 2 years [104].

5.2.3. Peripartum cardiomyopathy (PPCM)

This is defined as heart muscle disease in which left ventricular systolic dysfunction and symptoms of HF occur between the last month of pregnancy and the first 5 months postpartum. In many parts of Africa, the prevalence is about 1/1500 deliveries. However, the northern part of Nigeria appears to be the hot spot for the condition where it affects 1/100 women after delivery. Recent echocardiography-based study from this part of Nigeria confirms similar prevalence [111]. The epidemiology, pathophysiology and clinical features of this condition have been reviewed in detail elsewhere [112, 113, 114, 115]. Most patients present within the first 4 months after delivery. Only about 10% present in the last month of pregnancy.

Symptoms and signs are similar to other forms of systolic dysfunction. In addition, they are prone to thromboembolic phenomenon [116].

Aetiological factors implicated include multiparty, advanced maternal age, multiple gestation, preeclampsia, gestational hypertension and black race. Several plausible aetiological mechanisms have been advanced. These include genetic predisposition, myocarditis, cardiotropic viral infections, chimerism, apoptosis and inflammation. Others include abnormal haemodynamic response, immune complexes, cardiac nitric oxide synthase, immune dendritic cells, cardiac dystrophin, etc. [113, 117].

A novel molecular mechanism of PPCM has been documented. Such mechanisms include elevated pro-inflammatory markers such as sFas/Apo 1, interferon-gamma, interleukin-6 and C-reactive protein. These points to the pro-inflammatory mechanism in the initiation, progression and prognosis of the disease. A pathophysiological circuit that involves unbalanced oxidative stress which leads to enhanced cleavage of prolactin into pro-apoptotic and angiogenic 16-kDa sub-fragments has been described. This process results in endothelial damage and LV dysfunction. Presence of endothelial damage in PPCM is further supported by the presence of endothelial microparticles suggesting apoptosis with impaired microcirculation. Furthermore, the angiogenic imbalance in this condition may also be contributed by soluble fms-like tyrosine kinase [118].

About 23–54% of PPCM patients have normalization of LV function at 6 months. Poor outcome is associated with increased LV systolic dimension, lower body mass index and low serum cholesterol at the time of presentation. On the other hand, older age and smaller LV end-systolic diameter is associated with higher chances of recovery of LV function [118].

The mortality associated with PPCM is 15% at 6 months, 28% at 2 years and 42% in over 25 years of follow-up. Predictors of mortality include NYHA functional class at presentation, cardiothoracic ratio, electrocardiographic QRS duration and higher diastolic pressure [119, 120]. A proof-of-concept pilot study has provided some evidence of the benefit of bromocriptine in PPCM patients [121].

5.2.4. Other cardiomyopathies Hypertrophic cardiomyopathy

Earlier reports of this condition were mainly anecdotal and it was generally thought to be uncommon in Africa. The earliest report appears to be that of Lewis et al. in 1973 [122]. Thereafter, other reports followed [123, 124, 125, 126, 127]. In 1240 consecutive echocardiography in Ethiopia, the prevalence of HCM was 4.3% (54 subjects) and accounted for 34.4% of cardiomyopathies [128]. In a similar study in Tanzania, it accounted for 0.2% of 6680 echocardiograms [129]. HCM is the third commonest cardiomyopathy in Ghana [13].

The genetic studies done on this condition have emanated only from South Africa where facilities are available [130, 131, 132, 133, 134, 135, 136, 137, 138, 139]. The disease-causing genetic mutation or loci has been documented. These include beta-myosin heavy chain (MYH7) gene, myosin binding protein c (MYBPC3) gene and troponin T (TNNT2) gene. Carriers of T (TNNT2) R92W mutation develop cardiac hypertrophy after the age of 35 years. They also have abnormal response to exercise which may explain the high mortality associated with this mutation [140].

The physiological effects of genetic mutations that cause HCM have also been studied in the continent. TNNT R92W mutation is associated with a relative increase in LV systolic functional parameters. Reduced diastolic function has been demonstrated in MYH7 A797T mutation, while MYH7 R403W mutation is associated with reduction in both systolic and diastolic functions [141, 142].

Furthermore, angiotensin II type 2 receptor (AGTR2) gene and angiotensin converting enzyme 2 (ACE2) gene have been identified as genetic risk factors (i.e. genetic polymorphism with evidence of association with HCM) [130, 143]. Arrhythmogenic right ventricular cardiomyopathy (ARVC)

The first report of ARVC from the region was in the year 2000 [144]. Kindred that are linked to ARVC type 6 locus have been documented [145]. The first multicentre registry of ARVC was reported from South Africa [146]. Data from the registry show that the disease occurs in all racial and ethnic groups in the country. Symptoms start from the third decade of life and the most common symptoms are palpitation, dizziness, syncope and chest pain. Symptoms are more pronounced in males. The reported male to female ratio is 2:1. About 28% were professional endurance athletes at some point in their lives. About 30% of the participants have family members who are also affected and 25% had plakophilin-2 gene defect [146, 147].

Interestingly, the rare ‘allele-dose-defect’ was demonstrated in one of the subjects, while haplotype analysis also demonstrated the uncommon ‘founder effect’ in many of the subjects [146, 147].

The annual mortality is 2.8% and 5-year cumulative mortality is 10% [146, 147]. Isolated left ventricular non-compaction (ILVNC)

Ker et al. [148] reported the first case of ILVNC in SSA in 2006. Since then, there have been reports from Djibouti [149], South Africa [150, 151] Sudan [152] and Nigeria [153]. The disorder is a common cause of HF, disorders of cardiac rhythm and cardioembolism and is as a result of failure of the myocardium to compact in utero.

In a series comprising of 54-ILVNC patients, Peters et al. [150] in Johannesburg showed that the prevalence is 6.9% and the mean age of presentation is 45.4 ± 13.1 years. It occurs commonly in males (55.6%) and majority (63.0%) present in NYHA class II. HF with systolic dysfunction is the common mode of presentation (98.1%). The identified sites of non-compaction include apical (100%), mid-inferior (74.1%) and mid-lateral walls (64.8%). The disorder has also been documented to be associated with pulmonary hypertension (83.3%), right ventricular (RV) dilation (74.1%) and impaired RV function (59.3%). HIV-associated cardiomyopathy

This is another cause of HF in Africa. Globally, the prevalence was 2–40% in the pre-highly active anti-retroviral treatment (Pre-HAART) era [154, 155]. However, with the introduction of HAART, the prevalence has fallen in many parts of the world. But in some parts of SSA, due to poverty, ignorance, weak health system, malnutrition and low utility of HAART, the high of HIV-associated cardiomyopathy is prevalent. The effectiveness of HAART is also supported by data from Uganda that showed low prevalence of this condition in children on this treatment [156].

The true prevalence of HIV-associated cardiomyopathy is unknown in the sub-region. Prevalence from reported literature ranges from 5% in Nigeria to 57% in Burkina Faso [157, 158, 159]. It is the commonest cardiac diagnosis in HIV-infected people in the Heart of Soweto study and more common in those with high viral load and lower CD4 count [160].


6. Pericardial diseases

Pericarditis and pericardial effusion are common in SSA and are frequently a cause of HF in the region. In some areas, over 15% of cardiovascular admission may be due to primary pericardial diseases. Tuberculosis is the leading cause of pericardial disease in Africa and this is often complicated by constrictive pericarditis. The burden of pericardial disease in SSA has escalated due to the impact of HIV/AIDS.

Next to tuberculosis is purulent pericarditis secondary to streptococcal or staphylococcal infection. Viruses may be responsible for most cases of benign pericarditis without demonstrable aetiology. Other causes include parasitic infections such as trypanosomiasis and malaria.


7. Congenital heart disease

Few publications have looked at cardiovascular disease in young Africans despite the fact that two-thirds of the population of SSA are made up of children and young adults. Congenital heart diseases constitute about 0.3% of heart diseases seen in northern Nigeria [161] to 12% in the series documented by Bertrand in Ivory Coast [162]. The high value in the later may be because the centre at a time served a large referral centre for cardiac surgery in West Africa.

A prevalence of 13.1% was documented in Cameroon (mean age: 10 ± 9 years, range: 2 months–41 years) [163]. About 35% of children with HF in Uganda have congenital heart disease [109].

To the best of our knowledge, the only population-based data on congenital heart disease is from Mozambique where the prevalence was reported as 2.3/1000 children [164].

The pattern of cardiac lesions appears not to be different from reports from other parts of the world in terms of the most frequent lesions. In the decreasing order of frequency, ventricular septal defect, atrial septal defect, Fallot’s tetralogy and patent ductus arteriosus are the common congenital heart diseases that may lead to cardiac failure in Africa [164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179]. Recognition of cyanosis in the dark skin may pose a challenge coupled with the fact that anaemia is common in SSA population.

Lack of trained man power, scarcity of diagnostic tools as well as poverty mitigates the care of patients with congenital heart disease in the region.


8. Coronary artery disease

It is generally believed that coronary artery disease is uncommon in SSA. However, recent reports emanating from the region suggest that the disease is emerging, and when it occurs, the clinical as well as the pathological features are similar to that seen in Caucasians [180]. In early reports, Edington [181] in 1954 noted only 3 cases in about 3500 consecutive autopsies in present-day Ghana. Sharper and Williams [5] documented nine cases seen in Uganda over a 3-year period (1955–1957). Falase et al. [182] reported 26 cases over a period spanning 1961–1970 and calculated a prevalence rate of 1:20,500 for Ibadan, Nigeria. In another study by the same author, the prevalence has increased to 1:10,000. Okuwobi [183] saw seven cases over a period of 3 years. Bertrand [184] reported 75 cases over a 6-year period and this accounted for 0.83% of total cardiac-related admission.

Recent reports still report low prevalence of this condition but the trend is that it is on the increase. In a study of HF in elderly subjects (60 years and above), Ikama and his colleagues reported a prevalence of 25.6% in this age group [185].

Studies done in South Africa between 1992 and 2008 show remarkable increase in the prevalence of the disease. In 1994, the prevalence was 0.2% [186] but the recent report from the Heart of Soweto study shows a prevalence of about 10%. This is remarkable evidence of gradual shift in disease pattern (epidemiologic transition) in this population. The prevalence reported in earlier studies ranged from 0.4 to 1.0% [187, 188, 189].


9. Pulmonary heart disease (cor pulmonale) and pulmonary hypertension

This is also emerging as a common cause of heart disease in SSA. In the Heart of Soweto study, right HF or cor pulmonale was documented in 27% of individuals admitted for HF. The prevalence in other regions is as follows: 0.8–9.5% in West Africa and 0.3–7.7% in Eastern Africa.

At least six reports have looked at the aetiology of pulmonary heart disease in SSA [190, 191, 192, 193, 194, 195]. The common aetiological factors described include left heart disease, chronic obstructive pulmonary disease, bronchiectasis, tuberculosis, bronchial asthma, pulmonary fibrosis of unknown origin, pulmonary embolism (acute cor pulmonale), HIV/AIDs and thromboembolic obliterative pulmonary hypertension.

Tuberculosis and chronic obstructive pulmonary disease is the major culprit. The situation is worsened by the emergence of HIV/AIDS. Globally, there has been an increase in the incidence of tuberculosis by 2.2 million from 1997 to 2005 and 95% of this is occurring in developing countries. In a recent autopsy report from South Africa, it was reported that 31% of cases had pulmonary hypertension as cause or part of their cardiac lesion.

HIV-associated pulmonary hypertension is being increasingly reported in SSA [196]. Hakim et al. [197] and Niakara et al. [158] recently reported a prevalence of 5%. Other causes of pulmonary hypertension in SSA include sickle cell anaemia [198], connective tissue disease, congenital heart disease [199], valvular heart disease [74], schistosomiasis [200, 201], laryngeal papillomatosis [202], sarcoma [203], herbal remedies [204], hypertensive disorders of pregnancy [205], vaso-occlusive disorders [206] and primary pulmonary hypertension [207].


10. Gender differences

In the THESUS HF registry, men were significantly older and presented in poorer NYHA functional class. Men are also more likely to be current or previous smokers and have higher blood pressure. Renal dysfunction, poorer left ventricular ejection fraction and higher transmitral E/A ratio are also more frequent in men. Atrial fibrillation, anaemia and valvular heart disease are significantly more common in women [216].

11. Regional differences

Hypertensive HF as aetiological risk factor for HF is less reported in countries in the horn of Africa, for example, Ethiopia, Eritrea and Djibouti contrary to reports from west and central Africa [18]. Ischaemic heart disease is now the commonest cause of HF in Sudan (an example of country undergoing rapid epidemiologic transition; see Figure 3) This explains the difference in the picture presented by the THESUS HF survey [27] and the African data in the INTER-CHF study [26, 40]. Data from Nigeria and Sudan predominated in the two studies, respectively. Cardiomyopathy appears to be commoner in southern and eastern (except Tanzania) parts of the continent. HIV-associated cardiomyopathy has been commonly reported from the southern region of the continent (Figure 4AD).

Figure 3.

Sudan epidemiologic transition.

12. Laboratory findings

12.1. 12-Lead ECG

ECG abnormalities are common in patients with HF in SSA [217, 218]. The common major ECG abnormalities are left ventricular hypertrophy, inverted T-wave, atrial fibrillation, Q waves compatible with myocardial infarction, premature ventricular and supraventricular beats and bundle branch blocks. Common minor abnormalities are axis deviation, ST-T changes, ST elevation, isolated pathological Q-wave and right ventricular hypertrophy [218].

In the THESUS HF study, a higher ventricular was associated with higher 180-day readmission or mortality. QRS duration and corrected QT interval were not associated with either composite of death or readmission through 60 days or death through 180 days [218].

12.2. Echocardiography

About 70% of HF patients in SSA have LV ejection fraction lower than 40% [17, 18, 19, 27]. This is associated with male gender, presence of pedal oedema, higher heart rate, lower blood pressure and renal dysfunction. Left atrial size among other clinical variables predicts rehospitalisation or death within 60 days. Left ventricular posterior wall added to clinical variables predicts 180-day mortality rates [219]. The recently described mid-range ejection fraction has not been fully described in Africa. In a recent retrospective report from Ghana, the distribution of HFrEF, HFmrEF and HFpEF are 23.2, 17.8 and 59%, respectively [220].

13. In-hospital care

13.1. Drug treatment

Loop diuretics are the commonest medication used for the treatment of HF in SSA (81.6, 95% CI: 72.7–89.1%) This is followed by angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (75%, 95% CI: 64.4–85.1%), aldosterone antagonists (51.5%, 95% CI: 32.4–70%), beta-blockers (31.4%, 95% CI: 22.6–40.9%) and digoxin (31.5%, 95% CI: 19.4–45%) [221, 222].

The use of nitrates is low (7.9%). Parenteral inotropes (dopamine and dobutamine) are uncommonly used (5.0 and 5.1%, respectively). Mechanical ventilation is rarely used (0.6%) [27].

13.2. Procedural investigations

Unlike in developed countries, the use of procedural investigations is not well documented in SSA. This is most likely due to limited access to these procedures, high cost as well as limited reports from various centres in the region.

14. Co-morbidities

14.1. Renal dysfunction

About 7.7–48% of HF patients in SSA have renal dysfunction. Worsening renal function occurs in about 10% of cases. This is commoner in West Africa. It is also associated with overweight/obesity and presence of basal crackles at admission. Presence of renal dysfunction is also independently associated with higher readmission rate over 60 days and all-cause mortality over 180 days [36].

14.2. Atrial fibrillation

In the THESUS HF survey, atrial fibrillation (AF) was documented in about 20%. Individuals with AF are older than the general HF population; they are more likely to be females and they have significantly higher heart rate but lower blood pressure. Presence of AF is not associated with poorer outcome; however, valvular AF is associated with all-cause readmission and mortality [223]. AF is associated with poorer outcome in Tanzania [19].

14.3. Anaemia

Rates of anaemia range from 8% in Abuja Nigeria to 64.3% in Uganda. Higher rates have been recorded in other East African countries and northern Nigeria [224, 225]. Iron deficiency anaemia occurs in about 57% of HF patients in Tanzania. This has been shown to be associated with poor prognosis. Table 2 shows the prevalence of anaemia in some SSA countries.

Authors Country Year Number % Anaemia Definition
Makubi [19] Tanzania 2014 427 57 <10 g/dl
Ogah [18] Nigeria (South) 2014 452 8.8 <10 g/dl
Damasceno [27] Multi-country 2012 1006 15.2 <10 g/dl
Stewart [17] South Africa 2008 699 10.0 Male, <11 g/dl, female <10 g/dl
Karaye [226] Nigeria (North) 2008 100 45% NA
Kuule [227] Uganda 2009 157 64.3 Male, ≤12.9 g/dl, female, ≤11.9 g/dl
Inglis [233] South Africa 2007 163 13.5 WHO
Dzudie [234] Cameroon 2008 140 15.7 NA

Table 2.

Prevalence of anaemia in some HF studies in SSA.

NA = not available.

14.4. Psychological dysfunction and depression

Psychological distress is common in SSA patients with HF. More than one-third (39%) have both depression and anxiety while about 16 and 13% have depression and anxiety respectively. Furthermore, two-thirds of in-patients and one-third of out-patients have depression [226, 227]. Psychological distress and depression is more common in young HF patients because of challenges of coping and adjusting with the condition [228].

14.5. Heart failure knowledge and compliance to treatment

HF patients in Africa have poor knowledge of their illness, the medications and side effects. The compliance to medications is also poor especially with diuretics because of the side effects. Ability to recall medications is also poor [229, 230].

15. Outcomes

15.1. Length of hospital stay

The median length of hospital stay ranges from 7 days in the THESUS HF survey, 11 days in Abeokuta, Nigeria and 13 days in a rural health facility in the Cameroun.

15.2. Readmission rate

Readmission after an initial or index case of HF is common, and CV reasons (worsening HF) are responsible in most of the cases. The rate of readmission or death at 60 days is about 15.4%.

15.3. Mortality

15.3.1. In-hospital mortality

The reported in-hospital mortality is in the range of 3.8–25.2% (see Figure 5) [18, 20, 24, 27, 29, 30, 233].

Figure 5.

Intra-hospital mortality from various HF studies in SSA.

Figure 4.

Spectrum of aetiology of HF in various studies in SSA.

15.3.2. Short- and medium-term mortality

Thirty-day mortality rate ranges from 14.7 to 35% [221, 234]. The reported 60- and 180-days readmission or mortality is 15–57.8 and 21.9–57.9%, respectively. Common predictors of readmission or mortality include presence of malignancy, severe lung disease, admission for blood pressure, heart rate, signs of congestion, renal function and ejection fraction. Others include anaemia, history of smoking and HIV co-infection [221, 234].

15.3.3. Long-term mortality

A 3-year mortality rate of 67.1% was reported in patients with advanced heart failure from one centre in Nigeria [212]. In a recent retrospective report from Ghana, the 1-, 2- and 5-year survival rates were reported as 90.3, 64.7 and 38.4%, respectively. Those with HFpEF are older, are more often women and often have non-ischaemic etiology for the HF. They also have higher rates of CKD and atrial fibrillation but lower rates of DCM. On the other hand, those with HFrEF are more symptomatic and are more likely to receive disease-modifying medications [220]. Among individuals with HFpEF, anaemia, DCM, diabetes mellitus, presence of cerebrovascular event, use of statin and aldosterone antagonist independently predicted mortality. On the other hand, severe HF symptoms, history of smoking and use of beta-blockers were independent predictors of death in HFmrEF patients. Age is a predictor of mortality in all the three HF groups. HFpEF has a better long-term prognosis [220].

15.4. Quality of life (QoL) and spiritual well-being

Poor quality of life has been demonstrated in over 25% of HF patients in Nigeria. Age and educational attainment are major determinants of QoL [235]. In Kenya, spiritual distress is common and more often in younger patients [236].

15.5. Economic cost

In developing countries, about 15.1 billion US dollars was spent on the care of HF in the year 2012 [237]. The cost of HF in Nigeria in the year 2009 was estimated at 508,595 USD, translating to 2128 USD per patient per year. In-patient and out-patient care cost constituted 46 and 54% of total care cost, respectively. The relatively higher cost of out-patient care cost was attributed to the cost of transportation for monthly follow-up visits. Payment for the care of HF is out-of-pocket in most parts of SSA.

16. Comparison with other parts of the world

Compared to other regions of the world, HF patients in SSA are younger. The mean age in the THESUS HF survey [27] was 52 years compared to 69.9 years in the EURO HF survey, 72.4 years in the ADHERE study (in USA, 71 years in Japan and 60 years in Indonesia; Table 3) [27].

Study No % Women Mean age Smoking Hypertension Diabetes Anaemia CKD NYHA (III & IV) Mean EF HHF DCM VHDX RHF IHD LOS M
THESUS_HFS [27] 1006 50.7 52 9.8 55.5 11.1 15.2 7.7 34.6 39.5 45.4 18.8 14.3 NR 7.7 7 4.2
EuroHeart failure [243] 3580 38.7 69.9 NR 62.5 32.8 14.7 16.8 NR 38 11.4 19.3 3.2 53.6 9 6.7
ADHERE, USA 105,388 52 72.4 NR 73 44 NR 30 76 34.4 4.3 4
OPTIMIZE, USA 48,612 52 73 NR NR NR NR NR NR 39 3.8
ADHERE, Indonesia 1687 64.5 60 74 54.8 31.2 NR NR NR 37.9 54.8 NR NR NR 23.3 7.1 6.7
JCARE-CARD, Japan 2675 40.3 71 37.7 52.9 29.9 20.8 11.7 87.5 42.2 24.6 21.9 15.7 NR 32 NR NR

Table 3.

Comparison of present study with other HF studies in SSA and other parts of the world.

EF = ejection fraction, NYHA = New York Heart Association, CKD = chronic kidney disease, HHF = hypertensive heart failure, DCM = dilated cardiomyopathy, VHDX = valvular heart disease, RHF = right heart failure, IHD = ischaemic heart disease, LOS = length of stay in hospital, M = intra-hospital mortality.

They are more likely to have rheumatic heart disease as the aetiology, while ischemic heart disease is less likely. They are also relatively less likely to have diabetes mellitus, atrial fibrillation and chronic obstructive airway disease as co-morbidity. The prevalence of chronic kidney disease and anaemia is lower in SSA HF patients. The mean left ventricular EF and median length of hospital stay appear to be similar to other parts of the world [27]. In the INTER-CHF study, the age-adjusted mortality is worse in SSA compared to other low- and middle-income regions [27].

17. Gaps and future directions

There is generally no population-based incidence or prevalence data on HF in SSA. The community or population-based data on the burden of systolic or diastolic dysfunction using echocardiography is unknown. In addition, apart from high blood pressure, the community burden of other aetiological risk factors for HF such as EMF, rheumatic heart disease and right HF is largely scanty.

The molecular pathobiology of HF in SSA is largely unexplored. The secular trend in HF in SSA is also unknown. This has been well studied in high-income countries of Europe and North America. There is also need for research into best strategies for treatment and prevention of common causes of HF in the region. More cohort studies and longer follow-up of HF patients are needed in SSA to fully describe the natural history of HF. An in-depth cost analysis or economic analysis as well as data on quality of care is also scanty and needs exploring. Clinical trials on HF are generally lacking.

Finally, in-depth scientific approaches to better understand the epidemiology, pathobiology, socio-cultural factors, treatment patterns as well as outcome of HF and diseases leading to HF should be the focus of future research. As suggested by Fonn, ‘research conceptualized, conducted, analysed and published by Africans is crucial for Africa to meet the health needs of her people’ [238].

18. Conclusions

African HF patients are the youngest compared to most regions of the world. They are most likely to be illiterate and often lack medication or health insurance. They are most likely to be in the worst NYHA functional class and less likely to be on any beta-blocker.

Hypertensive heart disease is the commonest aetiological risk factor. Other risk factors include dilated cardiomyopathy, rheumatic heart disease and ischaemic heart disease. HF-related mortality is also high in SSA.


  1. 1. United Nations. World Population Prospects: The 2006 Revision Population Database. 2006. Available from:
  2. 2. Sub-Saharan Africa. Wikipedia: The Free Encyclopedia. 2009. Available from:
  3. 3. Cooke A. Notes on the disease met with in Uganda, Central Africa. Journal of Tropical Medicine. 1901;4:175-178
  4. 4. Vaughan JP. A brief review of cardiovascular disease in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1977;71(3):226-231
  5. 5. Shaper AG, Williams AW. Cardiovascular disorders at an African hospital in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1960;54:12-32
  6. 6. Shaper AG, Shaper L. Analysis of medical admissions to Mulago Hospital, 1957. East African Medical Journal. 1958;35(12):647-678
  7. 7. Lauckner JR, Rankin AM, Adi FC. Analysis of medical admissions to the University College Hospital Ibadan. West African Journal of Medicine. 1961;10:3-32
  8. 8. Turner PP. The pattern of disease as seen by medical admissions to the Coast Province General Hospital in 1960. East African Medical Journal. 1962;39:121-135
  9. 9. Nhonoli AM. Heart disease in Dar es Salaam. East African Medical Journal. 1968;45(3):118-121
  10. 10. Brown KG, Willis WH. Cardiac disease in Malawi. South African Medical Journal. 1975;49(23):926-930
  11. 11. Edginton ME, Hodkinson J, Seftel HC. Disease patterns in a South African rural Bantu population, including a commentary on comparisons with the pattern in urbanized Johannesburg Bantu. South African Medical Journal. 1972;46(28):968-976
  12. 12. Oyoo GO, Ogola EN. Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi. East African Medical Journal. 1999;76(1):23-27
  13. 13. Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. Cardiology. 2000;93(1-2):11-18
  14. 14. Kingue S et al. A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: Experience of the medicine department at Yaounde General Hospital. Annales de Cardiologie et d'Angéiologie (Paris). 2005;54(5):276-283
  15. 15. Ojji DB et al. Pattern of heart failure in Abuja, Nigeria: An echocardiographic study. Cardiovascular Journal of Africa. 2009;20(6):349-352
  16. 16. Sliwa K et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): A cohort study. Lancet. 2008;371(9616):915-922
  17. 17. Stewart S et al. Predominance of heart failure in the Heart of Soweto Study cohort: Emerging challenges for urban African communities. Circulation. 2008;118(23):2360-2367
  18. 18. Ogah OS et al. Contemporary profile of acute heart failure in Southern Nigeria: Data from the Abeokuta Heart Failure Clinical Registry. JACC: Heart Failure. 2014;2(3):250-259
  19. 19. Makubi A et al. Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: The prospective Tanzania Heart Failure (TaHeF) study. Heart. 2014;100(16):1235-1241
  20. 20. Okello S et al. Characteristics of acute heart failure hospitalizations in a general medical ward in Southwestern Uganda. International Journal of Cardiology. 2014;176(3):1233-1234
  21. 21. Boombhi J et al. Clinical pattern and outcome of acute heart failure at the Yaounde Central Hospital. Open Access Library Journal. 2017;4(03):1
  22. 22. Osuji CU et al. Pattern of cardiovascular admissions at Nnamdi Azikiwe University Teaching Hospital Nnewi, South East Nigeria. The Pan African Medical Journal. 2014;17:116-121
  23. 23. Massoure PL et al. Heart failure patterns in Djibouti: epidemiologic transition. Medecine et Sante Tropicales. 2013;23(2):211-216
  24. 24. Mwita JC et al. Presentation and mortality of patients hospitalised with acute heart failure in Botswana. Cardiovascular Journal of Africa. 2017;28(2):112
  25. 25. Abebe TB et al. Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: A retrospective cohort study. BMC Cardiovascular Disorders. 2016;16(1):232
  26. 26. Dokainish H et al. Heart failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. International Journal of Cardiology. 2016;204:133-141
  27. 27. Damasceno A et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Archives of Internal Medicine. 2012;172(18):1386-1394
  28. 28. Pio M et al. Epidemiology and etiology of heart failure in Lome. The Pan African Medical Journal. 2014;18:183
  29. 29. Kingery JR et al. Heart failure, post-hospital mortality and renal function in Tanzania: A prospective cohort study. International Journal of Cardiology. 2017;243:311-317
  30. 30. Ali K, Workicho A, Gudina EK. Hyponatremia in patients hospitalized with heart failure: A condition often overlooked in low-income settings. International Journal of General Medicine. 2016;9:267-273
  31. 31. Adeoti AO et al. Pattern and outcome of medical admissions in Ekiti state university teaching hospital, Ado-Ekiti-a 5 year review. American Journal of Medicine and Medical Sciences. 2015;5(2):92-98
  32. 32. Pio M et al. Young heart failure: Epidemiological, clinical and etiological aspects in the teaching hospital Sylvanus Olympio of Lome. Annales de Cardiologie et d'Angéiologie (Paris). 2014;63(4):240-244
  33. 33. Chansa P et al. Factors associated with mortality in adults admitted with heart failure at the University Teaching Hospital in Lusaka, Zambia. Medical Journal of Zambia. 2014;41(1):4-12
  34. 34. Ogah OS et al. Spectrum of heart diseases in a new cardiac service in Nigeria: An echocardiographic study of 1441 subjects in Abeokuta. BMC Research Notes. 2008;1(1):98
  35. 35. Traore F et al. Heart failure with preserved ejection fraction: A report about 64 cases followed at the Heart Institute of Abidjan. World Journal of Cardiovascular Diseases. 2017;7(09):285
  36. 36. Sani MU et al. Renal dysfunction in African patients with acute heart failure. European Journal of Heart Failure. 2014;16(7):718-728
  37. 37. Sliwa K et al. Readmission and death after an acute heart failure event: Predictors and outcomes in sub-Saharan Africa: Results from the THESUS-HF registry. European Heart Journal. 2013;34(40):3151-3159
  38. 38. Pallangyo P et al. Cardiorenal anemia syndrome and survival among heart failure patients in Tanzania: A prospective cohort study. BMC Cardiovascular Disorders. 2017;17(1):59
  39. 39. Kwan GF et al. A simplified echocardiographic strategy for heart failure diagnosis and management within an integrated noncommunicable disease clinic at district hospital level for sub-Saharan Africa. JACC: Heart Failure. 2013;1(3):230-236
  40. 40. Dokainish H et al. Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure study (INTER-CHF). American Heart Journal. 2015;170(4):627-634 e1
  41. 41. Kimani K et al. What is known about heart failure in sub-Saharan Africa: A scoping review of the English literature. BMJ Supportive & Palliative Care. 2017;7:122-127
  42. 42. Carlson S et al. Capacity for diagnosis and treatment of heart failure in sub-Saharan Africa. Heart. 2017;103(23):1874-1879
  43. 43. Laabes EP, Thacher TD, Okeahialam BN. Risk factors for heart failure in adult Nigerians. Acta Cardiologica. 2008;63(4):437-443
  44. 44. Donnison C. Blood pressure in the African natives: Its bearing upon aetiology of hyperplasia and arteriosclerosis. Lancet. 1929;1:6-7
  45. 45. Jex-Blake AJ. High blood pressure. East African Medical Journal. 1934;10:286-300
  46. 46. Vint FW. Postmortem findings in natives of Kenya. East African Medical Journal. 1937;13:332-340
  47. 47. Williams AW. The blood pressure of the Africans. East African Medical Journal. 1941;18:109-117
  48. 48. Davies JN. Pathology of Central African natives; Mulago Hospital post mortem studies. East African Medical Journal. 1948;25(12):454-467
  49. 49. Becker B. Cardiovascular disease in the Bantu and coloured races of South Africa. The South African Journal of Medical Sciences. 1946;11:1-107
  50. 50. Akinkugbe OO, Nicholson GD, Cruickshank JK. Heart disease in blacks of Africa and the Caribbean. Cardiovascular Clinics. 1991;21(3):377-391
  51. 51. Opie LH. Heart disease in Africa. Lancet. 2006;368(9534):449-450
  52. 52. Akosa AB, Armah H. Cardiomegaly in Ghana: An autopsy study. Ghana Medical Journal. 2005;39(4):122-127
  53. 53. Cooper RS, Amoah AG, Mensah GA. High blood pressure: The foundation for epidemic cardiovascular disease in African populations. Ethnicity & Disease. 2003;13(Suppl 2):S48-S52
  54. 54. Adeloye D. An estimate of the incidence and prevalence of stroke in Africa: A systematic review and meta-analysis. PLoS One. 2014;9(6):e100724
  55. 55. Steyn K et al. Risk factors associated with myocardial infarction in Africa: The INTERHEART Africa study. Circulation. 2005;112(23):3554-3561
  56. 56. Seedat YK. Perspectives of hypertension in black patients: Black vs. white differences. Journal of Cardiovascular Pharmacology. 1990;16(Suppl 7):S67-S70
  57. 57. Araoye MA, Olowoyeye O. The clinical spectrum of hypertensive heart failure: A point-score system for solving an old problem. East African Medical Journal. 1984;61(4):306-315
  58. 58. Muna WF. Cardiovascular disorders in Africa. World Health Statistics Quarterly. 1993;46(2):125-133
  59. 59. Dzudie A et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Global Heart. 2018;13(1):45-59
  60. 60. Heinmann HL. Cardiac disease among African Non-Europeans. British Medical Journal. 1929;i:344
  61. 61. Marijon E et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. The New England Journal of Medicine. 2007;357(5):470-476
  62. 62. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366(9480):155-168
  63. 63. Kimbally-Kaky G et al. Rheumatic heart disease in schoolchildren in Brazzaville. Medecine Tropicale (Mars). 2008;68(6):603-605
  64. 64. Beaton A et al. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. Circulation. 2012;125(25):3127-3132
  65. 65. Kane A et al. Echocardiographic screening for rheumatic heart disease: Age matters. International Journal of Cardiology. 2013;168(2):888-891
  66. 66. Anabwani GM, Bonhoeffer P. Prevalence of heart disease in school children in rural Kenya using colour-flow echocardiography. East African Medical Journal. 1996;73(4):215-217
  67. 67. Oli K, Asmera J. Rheumatic heart disease in Ethiopia: Could it be more malignant. Ethiopian Medical Journal. 2004;42(1):1-8
  68. 68. McLaren MJ et al. Epidemiology of rheumatic heart disease in black shcool children of Soweto, Johannesburg. British Medical Journal. 1975;3(5981):474-478
  69. 69. Marijon E et al. Echocardiographic screening for rheumatic heart disease. Bulletin of the World Health Organization. 2008;86(2):84
  70. 70. Tantchou Tchoumi JC et al. Occurrence, aetiology and challenges in the management of congestive heart failure in sub-Saharan Africa: Experience of the cardiac Centre in Shisong, Cameroon. The Pan African Medical Journal. 2011;8:11
  71. 71. Tantchou Tchoumi JC, Butera G. Rheumatic valvulopathies occurence, pattern and follow-up in rural area: The experience of the Shisong Hospital, Cameroon. Bulletin de la Société de Pathologie Exotique. 2009;102(3):155-158
  72. 72. Soliman EZ, Juma H. Cardiac disease patterns in northern Malawi: Epidemiologic transition perspective. Journal of Epidemiology. 2008;18(5):204-208
  73. 73. Ike SO. Echocardiographic analysis of valvular heart diseases over one decade in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(12):1214-1218
  74. 74. Sani MU, Karaye KM, Borodo MM. Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: An echocardiographic study. Cardiovascular Journal of Africa. 2007;18(5):295-299
  75. 75. Onwuchekwa AC, Ugwu EC. Pattern of rheumatic heart disease in adults in Maiduguri—North East Nigeria. Tropical Doctor. 1996;26(2):67-69
  76. 76. Jaiyesimi F, Antia AU. Childhood rheumatic heart disease in Nigeria. Tropical and Geographical Medicine. 1981;33(1):8-13
  77. 77. Jaiyesimi F, Antia AU. Prognostic factors in childhood rheumatic disease. Tropical and Geographical Medicine. 1981;33(1):14-38
  78. 78. Fadahunsi HO, Coker AO, Usoro PD. Rheumatic heart disease in Nigerian children: Clinical and preventive aspects. Annals of Tropical Paediatrics. 1987;7(1):54-58
  79. 79. Okoroma EO, Ihenacho IN, Anyanwu CH. Rheumatic fever in Nigerian children. A prospective study of 66 patients. American Journal of Diseases of Children. 1981;135(3):236-238
  80. 80. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: Epidemiology, management, and prevention in Africa. Circulation. 2005;112(23):3584-3591
  81. 81. Nkomo VT. Epidemiology and prevention of valvular heart diseases and infective endocarditis in Africa. Heart. 2007;93(12):1510-1519
  82. 82. Nkomo VT et al. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368(9540):1005-1011
  83. 83. Cole TO, Adeleye JA. Rheumatic heart disease and pregnancy in Nigerian women. Clinical Cardiology. 1982;5(4):280-285
  84. 84. Cole TO. Rheumatic fever and rheumatic heart disease in the tropics with particular reference to Nigeria. Nigerian Medical Journal. 1976;6(2):123-126
  85. 85. Gunther G, Asmera J, Parry E. Death from rheumatic heart disease in rural Ethiopia. Lancet. 2006;367(9508):391
  86. 86. Sliwa K et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: Insights from the heart of Soweto study. European Heart Journal. 2009;31(6):719-727
  87. 87. Falase AO, Sekoni GA, Adenle AD. Dilated cardiomyopathy in young adult Africans: A sequel to infections? African Journal of Medicine and Medical Sciences. 1982;11(1):1-5
  88. 88. Falase AO, Fabiyi A, Ogunba EO. Heart muscle disease in Nigerian adults: A multifactorial disease. African Journal of Medicine and Medical Sciences. 1977;6(4):165-176
  89. 89. Basile U et al. Thiamine deficiency and idiopathic cardiomegaly in Nigerian adults. A preliminary communication. The African Journal of Medical Sciences. 1973;4(4):465-469
  90. 90. Falase AO. Heart muscle disease among adult Nigerians: Role of nutritional factors in its aetiology. European Journal of Cardiology. 1979;10(3):197-204
  91. 91. Falase AO. Cardiomegaly of unknown origin among Nigerian adults: Role of hypertension in its aetiology. British Heart Journal. 1977;39(6):671-679
  92. 92. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart. 2007;93(10):1176-1183
  93. 93. Owor R, Rwomushana RJ. Familial congestive cardiomyopathy in Uganda. East African Medical Journal. 1975;52(7):372-375
  94. 94. Przybojewski JZ et al. Familial dilated (congestive) cardiomyopathy. Occurrence in two brothers and an overview of the literature. South African Medical Journal. 1984;66(1):26-30
  95. 95. Maharaj B, Hammond MG. HLA-A, B, DR, and DQ antigens in black patients with idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 1990;65(20):1402-1403
  96. 96. Maharaj B et al. HLA-A, B, DR, and DQ antigens in black patients with severe chronic rheumatic heart disease. Circulation. 1987;76(2):259-261
  97. 97. Mayosi BM et al. Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy. Journal of Medical Genetics. 1999;36(10):796-797
  98. 98. Sliwa K et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 2002;90(10):1118-1122
  99. 99. Davies JN, Ball JD. The pathology of endomyocardial fibrosis in Uganda. British Heart Journal. 1955;17(3):337-359
  100. 100. Davies JN. Endomyocardial fibrosis in Uganda. The Central African Journal of Medicine. 1956;2(9):323-328
  101. 101. Davies JN. The ridge in endomyocardial fibrosis. Lancet. 1968;1(7543):631-632
  102. 102. Hutt MSR et al. Cardiomyopathies. Bulletin of the World Health Organisation. 1965;33:257-288
  103. 103. Shaper AG. Cardiovascular disease in the tropics. II. Endomyocardial fibrosis. British Medical Journal. 1972;3(5829):743-746
  104. 104. Parry EH, Abrahams DG. The natural history of endomyocardial fibrosis. The Quarterly Journal of Medicine. 1965;34(136):383-408
  105. 105. Mocumbi AO et al. A population study of endomyocardial fibrosis in a rural area of Mozambique. The New England Journal of Medicine. 2008;359(1):43-49
  106. 106. Shaper AG. The geographical distribution of endomyocardial fibrosis. Pathology & Microbiology (Basel). 1970;35(1):26-35
  107. 107. Adi FC. Endomyocardial fibrosis in two brothers. British Heart Journal. 1963;25:684-688
  108. 108. Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis: Still a mystery after 60 years. PLoS Neglected Tropical Diseases. 2008;2(2):e97
  109. 109. Ellis J et al. Echocardiographic, chest X-ray and electrocardiogram findings in children presenting with heart failure to a Ugandan paediatric ward. Tropical Doctor. 2007;37(3):149-150
  110. 110. Akinwusi PO, Odeyemi AO. The changing pattern of endomyocardial fibrosis in South-West Nigeria. Clinical Medicine Insights: Cardiology. 2012;6:163-168
  111. 111. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethnicity & Disease. 2007;17(2):228-233
  112. 112. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368(9536):687-693
  113. 113. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: A systematic review. International Journal of Cardiology. 2009;131(2):168-179
  114. 114. Abboud J et al. Peripartum cardiomyopathy: A comprehensive review. International Journal of Cardiology. 2007;118(3):295-303
  115. 115. Tibazarwa K, Sliwa K. Peripartum cardiomyopathy in Africa: Challenges in diagnosis, prognosis, and therapy. Progress in Cardiovascular Diseases. 2010;52(4):317-325
  116. 116. Isezuo SA et al. Case report: Acute limb ischaemia and gangrene associated with peripartum cardiomyopathy. The Nigerian Postgraduate Medical Journal. 2005;12(3):237-240
  117. 117. Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: Causes, diagnosis, and treatment. Cleveland Clinic Journal of Medicine. 2009;76(5):289-296
  118. 118. Sliwa K et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2010;12(8):767-778
  119. 119. Adesanya CO et al. Peripartum cardiac failure. A ten year follow-up study. Tropical and Geographical Medicine. 1989;41(3):190-196
  120. 120. Ford L et al. The outcome of peripartum cardiac failure in Zaria, Nigeria. QJM: An International Journal of Medicine. 1998;91(2):93-103
  121. 121. Sliwa K et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study. Circulation. 2010;121(13):1465-1473
  122. 122. Lewis BS et al. Hypertrophic obstructive cardiomyopathy in the South African Bantu. South African Medical Journal. 1973;47(14):599-604
  123. 123. Colyn HJ, Kleynhans PH. Hypertrophic cardiomyopathy in the black population of South Africa. South African Medical Journal. 1990;77(3):165
  124. 124. Neutel JM, Myburgh DP. Apical hypertrophic nonobstructive cardiomyopathy in a pilot. Aviation, Space, and Environmental Medicine. 1987;58(10):1005-1008
  125. 125. Myburgh DP et al. Apical hypertrophic cardiomyopathy. A case report. South African Medical Journal. 1987;71(6):392-393
  126. 126. Przybojewski JZ, Blake RS. Hypertrophic non-obstructive apical cardiomyopathy. A case presentation and review of the literature. South African Medical Journal. 1984;66(13):492-498
  127. 127. Lewis BS et al. Hypertrophic cardiomyopathy in South African blacks. South African Medical Journal. 1983;63(8):266-270
  128. 128. Abegaz B. The impact of echocardiography in the diagnosis of hypertrophic cardiomyopathy. East African Medical Journal. 1990;67(8):556-567
  129. 129. Posen BM et al. Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. British Heart Journal. 1995;74(1):40-46
  130. 130. van der Merwe L et al. Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy. Human Genetics. 2008;124(1):57-61
  131. 131. Heradien M et al. Race and gender representation of hypertrophic cardiomyopathy or long QT syndrome cases in a South African research setting. Cardiovascular Journal of Africa. 2007;18(5):312-315
  132. 132. Moolman-Smook J et al. Identification of novel interactions between domains of myosin binding protein-C that are modulated by hypertrophic cardiomyopathy missense mutations. Circulation Research. 2002;91(8):704-711
  133. 133. Blair E et al. Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy. Circulation Research. 2002;90(3):263-269
  134. 134. Andersen PS et al. Myosin light chain mutations in familial hypertrophic cardiomyopathy: Phenotypic presentation and frequency in Danish and South African populations. Journal of Medical Genetics. 2001;38(12):E43
  135. 135. Moolman-Smook JC et al. Hypertrophic cardiomyopathy repealing tenets in South Africa. Cardiovascular Journal of South Africa. 2000;11(4):202-209
  136. 136. Moolman-Smook JC et al. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: A unique profile of both independent and founder events. American Journal of Human Genetics. 1999;65(5):1308-1320
  137. 137. Moolman-Smook JC et al. Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy. Journal of Medical Genetics. 1998;35(3):253-254
  138. 138. Moolman JC, Brink PA, Corfield VA. Identification of a novel Ala797Thr mutation in exon 21 of the beta-myosin heavy chain gene in hypertrophic cardiomyopathy. Human Mutation. 1995;6(2):197-198
  139. 139. Moolman JC, Brink PA, Corfield VA. Identification of a new missense mutation at Arg403, a CpG mutation hotspot, in exon 13 of the beta-myosin heavy chain gene in hypertrophic cardiomyopathy. Human Molecular Genetics. 1993;2(10):1731-1732
  140. 140. Revera M et al. Long-Term Follow-Up of R403W MYH7 and R92W TNNT2 HCM Families: Mutations Determine Left Ventricular Dimensions but Not Wall Thickness during Disease Progression. 2007
  141. 141. Revera M et al. Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovascular Research. 2008;77(4):687-694
  142. 142. Heradien M et al. Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations. Heart Rhythm. 2009;6(11):S18-S24
  143. 143. Carstens N et al. Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure. Journal of the Renin-Angiotensin Aldosterone System. 2011;12(3):274-280
  144. 144. Munclinger MJ, Patel JJ, Mitha AS. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. South African Medical Journal. 2000;90(1):61-68
  145. 145. Matolweni LO et al. Arrhythmogenic right ventricular cardiomyopathy type 6 (ARVC6): Support for the locus assignment, narrowing of the critical region and mutation screening of three candidate genes. BMC Medical Genetics. 2006;7:29
  146. 146. Watkins DA et al. Clinical features, survival experience, and profile of plakophylin-2 gene mutations in participants of the arrhythmogenic right ventricular cardiomyopathy registry of South Africa. Heart Rhythm. 2009;6(Suppl 11):S10-S17
  147. 147. Hendricks N, Watkins DA, Mayosi BM. Lessons from the first report of the arrhythmogenic right ventricular cardiomyopathy registry of South Africa. Cardiovascular Journal of Africa. 2010;21(3):129-130
  148. 148. Ker J, Van Der Merwe C. Isolated left ventricular non-compaction as a cause of thrombo-embolic stroke: A case report and review. Cardiovascular Journal of South Africa. 2006;17(3):146-147
  149. 149. Massoure PL et al. Rare cause of heart failure in an elderly woman in Djibouti: Left ventricular non compaction. Medecine Tropicale (Mars). 2011;71(5):505-507
  150. 150. Peters F et al. Isolated left ventricular noncompaction in sub-Saharan Africa: A clinical and echocardiographic perspective. Circulation. Cardiovascular Imaging. 2012;5(2):187-193
  151. 151. Peters F et al. Isolated left ventricular noncompaction in identical twins. The American Journal of Cardiology. 2012;110(8):1175-1179
  152. 152. Ali SK. Unique features of non-compaction of the ventricular myocardium in Arab and African patients. Cardiovascular Journal of Africa. 2008;19(5):241-245
  153. 153. Ogah OS et al. Isolated left ventricular noncompaction: Report of a case from Ibadan, Nigeria. Nigerian Journal of Cardiology. 2016;13(2):148
  154. 154. Sani MU et al. Human immunodeficiency virus (HIV) related heart disease: A review. Wiener Klinische Wochenschrift. 2005;117(3):73-81
  155. 155. Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart. 2013;99(16):1146-1153
  156. 156. Tukei VJ et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. Journal of Acquired Immune Deficiency Syndromes. 2012;59(3):274-280
  157. 157. Twagirumukiza M et al. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: A multicenter, observational, prospective, cohort study in Rwanda. Current HIV Research. 2007;5(1):129-137
  158. 158. Niakara A et al. Cardiovascular diseases and HIV infection: Study of 79 cases at the National Hospital of Ouagadougou (Burkina Faso). Bulletin de la Société de Pathologie Exotique. 2002;95(1):23-26
  159. 159. Olusegun-Joseph DA et al. Echocardiographic patterns in treatment-naive HIV-positive patients in Lagos, South-West Nigeria. Cardiovascular Journal of Africa. 2012;23(8):e1-e6
  160. 160. Sliwa K et al. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. European Heart Journal. 2012;33(7):866-874
  161. 161. Ladipo GO. Cardiac failure at Ahmadu Bello University Hospital, Zaria. Nigerian Medical Journal. 1978;8(2):96-99
  162. 162. Bertrand E, Coulibaly AO, Ticolat R. Statistiques 1988, 1989 et 1990 de I'Institut de Cardiologie d' Abidjan. Cardiologie Tropicale. 1991;17(68):151-155
  163. 163. Tantchou Tchoumi JC et al. Occurrence and pattern of congenital heart diseases in a rural area of sub-Saharan Africa. Cardiovascular Journal of Africa. 2011;22(2):63-66
  164. 164. Marijon E et al. Prevalence of congenital heart disease in schoolchildren of sub-Saharan Africa, Mozambique. International Journal of Cardiology. 2006;113(3):440-441
  165. 165. Sani MU, Mukhtar-Yola M, Karaye KM. Spectrum of congenital heart disease in a tropical environment: An echocardiography study. Journal of the National Medical Association. 2007;99(6):665-669
  166. 166. Bassili A et al. Congenital heart disease among school children in Alexandria, Egypt: An overview on prevalence and relative frequencies. Journal of Tropical Pediatrics. 2000;46(6):357-362
  167. 167. Bannerman CH, Mahalu W. Congenital heart disease in Zimbabwean children. Annals of Tropical Paediatrics. 1998;18(1):5-12
  168. 168. Kokou O et al. The use of Doppler echocardiography in the diagnosis of congenital heart disease in the Pediatric Department of CHU-Tokoin, at Lome (Togo). Santé. 1996;6(3):161-164
  169. 169. Jaiyesimi F, Antia AU. Congenital heart disease in Nigeria: A ten-year experience at UCH, Ibadan. Annals of Tropical Paediatrics. 1981;1(2):77-85
  170. 170. McLaren MJ, Lachman AS, Barlow JB. Prevalence of congenital heart disease in black schoolchildren of Soweto, Johannesburg. British Heart Journal. 1979;41(5):554-558
  171. 171. Antia AU. Congenital heart disease in Nigeria. Clinical and necropsy study of 260 cases. Archives of Disease in Childhood. 1974;49(1):36-39
  172. 172. Levin SE, Kanarek KS. The incidence of congenital heart disease in Johannesburg. A 5-year study of liveborn infants at the Queen Victoria Maternity Hospital. South African Medical Journal. 1973;47(40):1855-1858
  173. 173. van der Horst RL. The pattern and frequency of congenital heart disease among blacks. South African Medical Journal. 1985;68(6):375-378
  174. 174. van der Horst, R.L. and J. Wainwright, Congenital heart disease in the Bantu: An autopsy analysis of 123 cases. South African Medical Journal. 1969;43(20): p. 586-589
  175. 175. Wood JB, Serumaga J, Lewis MG. Congenital heart disease at necropsy in Uganda. A 16-years survey at Mulago Hospital, Kampala. British Heart Journal. 1969;31(1):76-79
  176. 176. Gupta B, Antia AU. Incidence of congenital heart disease in Nigerian children. British Heart Journal. 1967;29(6):906-909
  177. 177. Schrire V. Experience with congenital heart disease at Groote Schuur Hospital, Cape Town. An analysis of 1439 patients over an eleven-year period. South African Medical Journal. 1963;37:1175-1180
  178. 178. Caddell JL, Morton P. The pattern of congenital heart disease in Yoruba children of Western Nigeria. American Heart Journal. 1967;73(3):431-432
  179. 179. Caddell JL, Connor DH. Congenital heart disease in Ugandan children. British Heart Journal. 1966;28(6):766-767
  180. 180. Williams AO. Coronary atherosclerosis in Nigeria. British Heart Journal. 1971;33(1):95-100
  181. 181. Edington GM. Cardiovascular disease as a cause of death in the Gold Coast African. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1954;48(5):419-425
  182. 182. Falase AO, Cole TO, Osuntokun BO. Myocardial infarction in Nigerians. Tropical and Geographical Medicine. 1974;25(2):147-150
  183. 183. Okuwobi BO. Pattern of heart diseases in Lagos. East African Medical Journal. 1968;45(3):122-127
  184. 184. Bertrand E. Coronary heart disease in black Africans: An overview. East African Medical Journal. 1995;72(1):37-41
  185. 185. Ikama MS et al. Heart failure in elderly patients in Brazzaville, Congo: Clinical and etiologic aspects and outcome. Medecine Tropicale (Mars). 2008;68(3):257-260
  186. 186. Annual Report of Medical officer of Health. City of Johannesburg, Johannesburg. 1994
  187. 187. Cosnett JE. Heart disease in the Zulu: Especially cardiomyopathy and cardiac infarction. British Heart Journal. 1962;24:76-82
  188. 188. Schrire V. Heart disease in Southern Africa with special reference to ischaemic heart disease. South African Medical Journal. 1971;45(23):634-644
  189. 189. Schwartz MB, Schamroth L, Seftel HC. The pattern of heart disease in the urbanized Johannesburg African. Medical Proceedings. 1958;4:275
  190. 190. Sofowora EO. Pulmonary heart disease in Ibadan. Thorax. 1971;26(3):339-342
  191. 191. Turner PP. Pulmonary heart disease in Africans in Mombasa. East African Medical Journal. 1962;39:40-51
  192. 192. Okuwobi BO. Pattern of heart failure at Lagos University Teaching Hospital. The West African Medical Journal and Nigerian Practitioner. 1967;16(6):198-203
  193. 193. Toure NO et al. Chronic cor pulmonale: A study of 34 cases in the Dakar University Hospital Center Cardiology Department. Dakar Médical. 2000;45(2):108-112
  194. 194. Thienemann F et al. The causes, treatment, and outcome of pulmonary hypertension in Africa: Insights from the Pan African Pulmonary Hypertension cohort (PAPUCO) registry. International Journal of Cardiology. 2016;221:205-211
  195. 195. Dzudie A et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: High prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovascular Journal of Africa. 2018;29(4):208-212
  196. 196. Steenekamp JH, Simson IW, Theron W. Cardiovascular causes of death at Tshepong Hospital in 1 year, 1989-1990. A necropsy study. South African Medical Journal. 1992;81(3):142-146
  197. 197. Hakim JG, Matenga JA, Siziya S. Myocardial dysfunction in human immunodeficiency virus infection: An echocardiographic study of 157 patients in hospital in Zimbabwe. Heart. 1996;76(2):161-165
  198. 198. Aliyu ZY et al. Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American Journal of Hematology. 2008;83(6):485-490
  199. 199. Diop IB et al. Congenital cardiopathies: Anatomo-clinical, prognostic, and therapeutic features apropos of 103 cases seen at the cardiology Clinic of the Dakar University Hospital Center. Dakar Médical. 1995;40(2):181-186
  200. 200. Mpe MT. An uncommon cause of pulmonary hypertension. Cardiovascular Journal of South Africa. 2000;11(2):98-101
  201. 201. Turner PP. Schistosomal pulmonary arterial hypertension in East Africa. British Heart Journal. 1964;26:821-831
  202. 202. Grobbelaar J et al. Pulmonary hypertension due to recurrent juvenile laryngeal papillomatosis. International Journal of Pediatric Otorhinolaryngology. 2005;69(9):1279-1282
  203. 203. Govender D, Pillay SV. Right pulmonary artery sarcoma. Pathology. 2001;33(2):243-245
  204. 204. Heath D et al. A pulmonary hypertension-producing plant from Tanzania. Thorax. 1975;30(4):399-404
  205. 205. Desai DK et al. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. British Journal of Obstetrics and Gynaecology. 1996;103(6):523-528
  206. 206. McCulloch M et al. Angiographic features of 26 children with Takayasu's arteritis. Pediatric Radiology. 2003;33(4):230-235
  207. 207. Bouldouyre M et al. Primary arterial pulmonary hypertension and sildenafil: A case report from Dakar. Dakar Médical. 2006;51(2):78-80
  208. 208. Ansa VO et al. Seasonal variation in admission for heart failure, hypertension and stroke in Uyo, South-Eastern Nigeria. Annals of African Medicine. 2008;7(2):62-66
  209. 209. Makubi A et al. Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. Heart. 2015;101(8):592-599
  210. 210. Ojji D et al. A predominance of hypertensive heart failure in the Abuja Heart Study cohort of urban Nigerians: A prospective clinical registry of 1515 de novo cases. European Journal of Heart Failure. 2013;15(8):835-842
  211. 211. Onwuchekwa AC, Asekomeh GE. Pattern of heart failure in a Nigerian teaching hospital. Vascular Health and Risk Management. 2009;5:745-750
  212. 212. Familoni OB, Olunuga TO, Olufemi BW. A clinical study of pattern and factors affecting outcome in Nigerian patients with advanced heart failure. Cardiovascular Journal of Africa. 2007;18(5):308-311
  213. 213. Owusu I. Causes of heart failure as seen in Kumasi, Ghana. Internet Journal of Third World Medicine. 2007;5:201-214
  214. 214. Kingue S et al. A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: Experience of the medicine department at Yaounde General Hospital. Annales de Cardiologie et d'Angeiologie. 2005;54(5):276-283
  215. 215. Thiam M. Cardiac insufficiency in the African cardiology milieu. Bulletin de la Societe de Pathologie Exotique (1990). 2003;96(3):217-218
  216. 216. Ogah OS et al. Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: Results of the THESUS-HF study. Clinical Research in Cardiology. 2015;104(6):481-490
  217. 217. Lee G et al. Are ECG abnormalities common in black Africans with heart failure? Results from the Heart of Soweto Study. SA Heart. 2008;5(1):4-11
  218. 218. Dzudie A et al. Prognostic significance of ECG abnormalities for mortality risk in acute heart failure: Insight from the sub-Saharan Africa survey of heart failure (THESUS-HF). Journal of Cardiac Failure. 2014;20(1):45-52
  219. 219. Sani MU et al. Echocardiographic predictors of outcome in acute heart failure patients in sub-Saharan Africa: Insights from THESUS-HF. Cardiovascular Journal of Africa. 2017;28(1):60-67
  220. 220. Bonsu KO et al. Clinical characteristics and prognosis of patients admitted for heart failure: A 5-year retrospective study of African patients. International Journal of Cardiology. 2017;238:128-135
  221. 221. Nyaga UF et al. Data on the epidemiology of heart failure in sub-Saharan Africa. Data in Brief. 2018;17:1218-1239
  222. 222. Gallagher J et al. Heart failure in sub-Saharan Africa. Cardiac Failure Review. 2018;4(1):21-24
  223. 223. Sani MU et al. Prevalence, clinical characteristics and outcomes of valvular atrial fibrillation in a cohort of African patients with acute heart failure: Insights from the THESUS-HF registry. Cardiovascular Journal of Africa. 2018;29(3):139-145
  224. 224. Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian Tertiary Medical Centre: A cross-sectional study. BMC Cardiovascular Disorders. 2008;8:16
  225. 225. Kuule JK, Seremba E, Freers J. Anaemia among patients with congestive cardiac failure in Uganda—Its impact on treatment outcomes. South African Medical Journal. 2009;99(12):876-880
  226. 226. Ola BA et al. Relationship between depression and quality of life in Nigerian outpatients with heart failure. Journal of Psychosomatic Research. 2006;61(6):797-800
  227. 227. Ansa VO et al. Psychological distress in Nigerian patients with heart failure. CVD Prevention and Control. 2009;4(4):207-211
  228. 228. Mbakwem AC, Aina OF. Comparative study of depression in hospitalized and stable heart failure patients in an urban Nigerian teaching hospital. General Hospital Psychiatry. 2008;30(5):435-440
  229. 229. Verena R et al. Medication adherence, self-care behaviour and knowledge on heart failure in urban South Africa: The heart of Soweto study. Cardiovascular Journal of Africa. 2010;21(2):86
  230. 230. Bhagat K, Mazayi-Mupanemunda M. Compliance with medication in patients with heart failure in Zambabwe. East African Medical Journal. 2001;78(1):45-48
  231. 231. Inglis SC et al. Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy. European Journal of Heart Failure. 2007;9(4):384-390
  232. 232. Dzudie A et al. Chronic heart failure, selected risk factors and co-morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. European Journal of Heart Failure. 2008;10(4):367-372
  233. 233. Tantchou TJ et al. Occurrence, aetiology and challenges in the management of congestive heart failure in sub-Saharan Africa: Experience of the Cardiac Centre in Shisong, Cameroon. Pan African Medical Journal. 2011;8:11(1):11-18
  234. 234. Agbor VN et al. Heart failure in sub-Saharan Africa: A contemporaneous systematic review and meta-analysis. International Journal of Cardiology. 2018;257:207-215
  235. 235. Mbakwem A et al. Comparative analysis of the quality of life of heart failure patients in South Western Nigeria. World Journal of Cardiovascular Diseases. 2013;3(1):146-153
  236. 236. Kimani KN, Murray SA, Grant L. Spiritual issues of people living and dying with advanced heart failure in Kenya: A qualitative serial interview study. BMJ Global Health. 2016;1(3):e000077
  237. 237. Cook C et al. The annual global economic burden of heart failure. International Journal of Cardiology. 2014;171(3):368-376
  238. 238. Fonn S et al. ’Birth to Ten’—Pilot studies to test the feasibility of a birth cohort study investigating the effects of urbanisation in South Africa. South African Medical Journal. 1991;79(8):449-454
  239. 239. Nieminen MS et al. EuroHeart failure survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. European Heart Journal. 2006;27(22):2725-2736
  240. 240. Adams KF Jr et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). American Heart Journal. 2005;149(2):209-216
  241. 241. Fonarow GC et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF registry. Journal of the American College of Cardiology. 2007;50(8):768-777
  242. 242. Siswanto BB et al. Heart failure in NCVC Jakarta and 5 hospitals in Indonesia. CVD Prevention and Control. 2010;5:35-38
  243. 243. Tsuchihashi-Makaya M et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs. preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circulation Journal. 2009;73(10):1893-1900

Written By

Okechukwu S. Ogah, Adewole Adebiyi and Karen Sliwa

Submitted: May 1st, 2018 Reviewed: November 6th, 2018 Published: May 20th, 2019